Nectar Lifesciences profit and loss

Latest FY26

Revenue: ₹0.0cr−100.0% on FY25
EBITDA: −₹60.7cr−₹26.5 cr in FY25
Net profit: −₹293cr−₹114 cr in FY25
EPS: −₹13.40−₹5.07 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	5.0	0.0	1,673	1,686	1,525	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	12.3	9.3	1.9	13.0	42.2
	17.3	9.3	1,675	1,699	1,567
	3.4	0.0	1,251	1,242	1,201
	0.0	0.0	0.0	0.0	0.0
	−0.1	0.0	117	−40.2	−41.6
	3.7	1.9	96.5	84.7	77.8
	36.3	36.1	74.6	87.1	79.5
	0.5	0.3	62.4	60.7	59.1
	87.1	58.8	235	246	234
	131	97.2	1,836	1,680	1,609
	−89.2	−60.7	−26.5	153	53.9
	−89.7	−61.0	−88.8	92.4	−5.2
Profit
	−114	−87.9	−162	18.3	−42.4
	88.2	0.0	0.0	0.0	0.0
	−25.5	−87.9	−162	18.3	−42.4
	−39.8	−30.5	−47.9	13.3	−18.2
	−39.8	−30.5	−47.9	13.3	−18.2
	−245	−293	−114	5.0	−24.2
	14.4	−57.3	−114	5.0	−24.2
	−259	−236	0.0	0.0	0.0
	0.1	0.1	0.5	−0.3	0.9
	−245	−293	−113	4.7	−23.3
	—	—	—	5.0	−24.2
Per share
	−₹11.37	−₹13.40	−₹5.07	₹0.22	−₹1.08
	−₹11.37	−₹13.40	−₹5.07	₹0.22	−₹1.08
Continuing & discontinued operations
	−439	−374	0.0	0.0	0.0
	−180	−139	0.0	0.0	0.0
Other comprehensive income — detail
	—	0.1	0.5	—	—
	—	0.1	0.5	−0.5	0.3
	—	0.0	0.0	—	—
	—	—	—	−0.2	0.1
	—	0.0	—	0.0	1.1
	—	0.0	—	—	—
	—	—	—	0.0	0.4
	—	—	—	5.0	−24.2
Per share — as-filed variants
	₹0.35	−₹2.62	−₹5.07	₹0.22	−₹1.08
	₹0.35	−₹2.62	−₹5.07	₹0.22	−₹1.08
	−₹11.72	−₹10.78	₹0.00	₹0.00	₹0.00
	−₹11.72	−₹10.78	₹0.00	₹0.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1.6	—	305	483	365
	32.8%	—	18.2%	28.7%	24.0%
Adjusted (ex-exceptional items) — derived
	−114	−87.9	−162	18.3	−42.4
	88.2	0.0	0.0	0.0	0.0
	−280	−293	−114	5.0	−24.2
	−₹13.01	−₹13.40	−₹5.07	₹0.22	−₹1.08

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NECLIFE₹10.34

Nectar Lifesciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersAAREYDRUGS NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹201 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,524.6	1,685.6	1,673.1	0.0	5.0
Other Income	42.2	13.0	1.9	9.3	12.3
Total Income	1,566.8	1,698.7	1,675.0	9.3	17.3
Expenses
+ Cost of Materials Consumed	1,200.8	1,242.4	1,250.7	0.0	3.4
+ Purchases of Stock-in-Trade	0.0	0.0	0.0	0.0	0.0
+ Changes in Inventories	-41.6	-40.2	117.3	0.0	-0.1
+ Employee Benefit Expense	77.8	84.7	96.5	1.9	3.7
+ Finance Costs	79.5	87.1	74.6	36.1	36.3
+ Depreciation & Amortisation	59.1	60.7	62.4	0.3	0.5
+ Other Expenses	233.6	245.6	235.0	58.8	87.1
Total Expenses	1,609.3	1,680.4	1,836.5	97.2	130.9
EBITDA	53.9	153.1	-26.5	-60.7	-89.2
EBIT	-5.2	92.4	-88.8	-61.0	-89.7
Profit
PBT before Exceptional Items	-42.4	18.3	-161.5	-87.9	-113.6
+ Exceptional Items	0.0	0.0	0.0	0.0	88.2
Pretax Income	-42.4	18.3	-161.5	-87.9	-25.5
+ Deferred Tax	-18.2	13.3	-47.9	-30.5	-39.8
Tax Expense	-18.2	13.3	-47.9	-30.5	-39.8
Net Income	-24.2	5.0	-113.7	-292.9	-245.1
+ Net Income — Continuing Ops	-24.2	5.0	-113.7	-57.3	14.4
+ Net Income — Discontinued Ops	0.0	0.0	0.0	-235.5	-259.4
+ Other Comprehensive Income	0.9	-0.3	0.5	0.1	0.1
Total Comprehensive Income	-23.3	4.7	-113.1	-292.8	-245.0
Net Income to Common	-24.2	5.0	—	—	—
Per Share
Basic EPS	-1.08	0.22	-5.07	-13.40	-11.37
Diluted EPS	-1.08	0.22	-5.07	-13.40	-11.37
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	0.0	-374.3	-439.3
+ Tax — Discontinued Operations	0.0	0.0	0.0	-138.7	-179.9
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.5	0.1	—
+ Items NOT to be Reclassified to P&L	0.3	-0.5	0.5	0.1	—
+ Tax on Items NOT to be Reclassified	—	—	0.0	0.0	—
+ Tax on Items NOT to be Reclassified — alt tag	0.1	-0.2	—	—	—
+ Items to be Reclassified to P&L	1.1	0.0	—	0.0	—
+ Tax on Items to be Reclassified	—	—	—	0.0	—
+ Tax on Items to be Reclassified — alt tag	0.4	0.0	—	—	—
Comprehensive Income — Owners of Parent	-24.2	5.0	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-1.08	0.22	-5.07	-2.62	0.35
Diluted EPS — Continuing Operations	-1.08	0.22	-5.07	-2.62	0.35
Basic EPS — Discontinued Operations	0.00	0.00	0.00	-10.78	-11.72
Diluted EPS — Discontinued Operations	0.00	0.00	0.00	-10.78	-11.72
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	365.3	483.4	305.1	—	1.6
Gross Margin %	23.96	28.68	18.23	—	32.79
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-42.4	18.3	-161.5	-87.9	-113.6
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	88.2
Net Income Adj (tax-effected)	-24.2	5.0	-113.7	-292.9	-280.3
EPS Adj	-1.08	0.22	-5.07	-13.40	-13.01
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	22.4	22.4	22.4	19.4	19.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.